Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

241
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
241
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

359
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
359
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

265
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
265
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

291
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
291
Inhaled Medications01:23

Inhaled Medications

288
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
288
Nose and Nasal Cavity01:24

Nose and Nasal Cavity

2.7K
The nose is composed of an observable exterior segment (external nose) and an internal segment within the skull known as the nasal cavity (internal nose). The external nose, visible on the face, consists of a framework of bone and hyaline cartilage enveloped in skin and muscle and lined with a mucous membrane. This structure is supported by the frontal bone, nasal bones, and maxillary bone and is supplemented by a cartilaginous framework comprising the septal nasal cartilage, lateral nasal...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Acting Insulin and Hypoglycemia in Critically Ill Patients with Diabetes: A Sensitivity Analysis.

Journal of intensive care medicine·2026
Same author

Academic conference posters: A systematic review.

Innovations in pharmacy·2026
Same author

Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study.

Journal of pharmacy practice·2026
Same author

Research and Scholarly Methods: Scoping Reviews.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Evaluation of the Safety and Effectiveness of Two Nomograms for the Management of Diabetic Ketoacidosis.

Hospital pharmacy·2026
Same author

Aspirin Deprescribing Interventions for Primary Prevention: A Systematic Review and Proposed Guidance for Deprescribing.

Pharmacotherapy·2026

Related Experiment Video

Updated: Jul 12, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K

Zavegepant Intranasal Spray for Migraines.

Amber Lanae Martirosov1, Christopher Giuliano2, Macy Shupp3

  • 1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Henry Ford Hospital, Detroit, MI, USA.

The Annals of Pharmacotherapy
|October 28, 2023
PubMed
Summary

Intranasal zavegepant offers effective acute treatment for migraine, showing significant pain freedom and relief from bothersome symptoms compared to placebo. This new migraine medication may provide a convenient alternative for patients.

Keywords:
BHV-3500CGRP receptor antagonist and migraineZavzpretmigrainezavegepant

More Related Videos

Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

59.2K
Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
05:44

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Published on: November 14, 2018

20.2K

Related Experiment Videos

Last Updated: Jul 12, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K
Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

59.2K
Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery
05:44

Novel Methods for Intranasal Administration Under Inhalation Anesthesia to Evaluate Nose-to-Brain Drug Delivery

Published on: November 14, 2018

20.2K

Area of Science:

  • Pharmacology and clinical trial data analysis.
  • Migraine treatment research.

Background:

  • Migraine is a common neurological disorder requiring effective acute treatments.
  • Intranasal zavegepant (BHV-3500) has emerged as a potential therapeutic option.

Purpose of the Study:

  • To review the pharmacology, efficacy, and safety of intranasal zavegepant for acute migraine treatment.
  • Evaluate zavegepant's potential as an alternative to existing therapies like triptans.

Main Methods:

  • Systematic literature search of PubMed, Embase, and ClinicalTrials.gov for studies on zavegepant (Zavzpret) and migraine.
  • Inclusion of English articles from January 2013 to September 2023 focusing on pharmacology, safety, efficacy, and clinical trials.

Main Results:

  • Phase 2/3 trials demonstrated zavegepant (10 and 20 mg) superiority over placebo in achieving pain freedom and reducing most bothersome symptoms (MBSs) at 2 hours.
  • Phase 3 trial confirmed zavegepant 10 mg's efficacy, with statistically significant improvements in pain freedom and MBS relief compared to placebo.
  • Adverse events like dysgeusia and nasal discomfort were reported but generally mild and comparable to placebo.

Conclusions:

  • Intranasal zavegepant is indicated for the acute treatment of migraine with or without aura in adults.
  • Its administration and rapid symptom relief present a potentially attractive alternative to triptans for migraine sufferers.
  • Zavegepant represents a convenient and effective new option for managing acute migraine episodes.